Supernus Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US8684591089

SecuritySUPN / Supernus Pharmaceuticals, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership109,457 shares
Latest Disclosed Value $ 5,440,014
Barclays Plc ownership in SUPN / Supernus Pharmaceuticals, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 109,457 shares of Supernus Pharmaceuticals, Inc. (US:SUPN) valued at $5,440,013 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 231,189 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of -52.65% during the quarter. The current value of the position is $4,819,939 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (SUPN) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

SUPN / Supernus Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 109,457 -121,732 -52.65 5,440 -50.76 0.0013
2026-03-31 2025-09-30 13F/A-3 SUPERNUS PHARMACEUTICALS COM 868459108 231,189 90,250 64.03 11,049 148.72 0.0024
2026-03-19 2025-09-30 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 108,788 -32,151 3,392 0.0009
2025-11-12 2025-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 231,189 90,250 11,049 0.0024
2026-02-27 2025-06-30 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 140,939 40,929 40.92 4,442 35.63 0.0010
2025-08-14 2025-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 140,939 40,929 4 0.0010
2025-08-13 2025-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 140,939 40,929 4 0.0003
2026-03-17 2025-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 100,010 -22,839 -18.59 3,275 -26.27 0.0009
2025-05-15 2025-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 100,010 -22,839 3 0.0009
2026-03-19 2024-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 122,849 14,061 12.93 4,442 30.96 0.0012
2025-02-13 2024-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 122,849 14,061 4 0.0012
2026-03-31 2024-09-30 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 108,788 51,005 88.27 3,392 119.55 0.0009
2024-11-19 2024-09-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 108,788 51,005 3 0.0009
2024-11-15 2024-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 108,788 51,005 3 0.0009
2026-03-23 2024-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 57,783 -22,793 -28.29 1,546 -43.78 0.0005
2024-08-14 2024-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 57,783 -22,793 2 0.0005
2026-03-24 2024-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 80,576 -22,223 -21.62 2,748 -7.63 0.0010
2024-05-15 2024-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 80,576 -22,223 3 0.0010
2026-03-25 2023-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 102,799 47,955 87.44 2,975 96.76 0.0011
2024-02-15 2023-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 102,799 47,955 3 0.0011
2026-03-26 2023-09-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 54,844 1,021 1.90 1,512 -6.49 0.0009
2023-11-07 2023-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 54,844 1,021 2 0.0009
2026-03-30 2023-06-30 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 53,823 8,585 18.98 1,618 -1.28 0.0010
2023-09-20 2023-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 53,823 8,585 2 0.0010
2023-08-03 2023-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 53,823 8,585 2 0.0010
2026-03-30 2023-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 45,238 636 1.43 1,639 3.02 0.0008
2023-05-04 2023-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 45,238 636 2 0.0008
2026-03-30 2022-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 44,602 -6,337 -12.44 1,591 -7.72 0.0007
2023-02-13 2022-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 44,602 -6,337 2 0.0007
2022-11-03 2022-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 50,939 1,449 2.93 1,723 20.41 0.0019
2022-08-12 2022-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 49,490 -17,556 -26.19 1,431 -33.96 0.0009
2022-05-16 2022-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 67,046 -10,552 -13.60 2,167 -4.24 0.0017
2022-02-23 2021-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 77,598 15,098 24.16 2,263 35.75 0.0008
2022-02-14 2021-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 77,598 15,098 2,263 0.0008
2021-11-09 2021-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 62,500 28,132 81.86 1,667 57.56 0.0008
2021-08-13 2021-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 34,368 -72,390 -67.81 1,058 -62.15 0.0005
2021-05-13 2021-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 106,758 -13,929 -11.54 2,795 -7.94 0.0015
2021-02-11 2020-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 120,687 -34,941 -22.45 3,036 -6.41 0.0016
2020-11-12 2020-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 155,628 15,535 11.09 3,244 -2.49 0.0019
2020-08-12 2020-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 140,093 46,651 49.93 3,327 97.80 0.0026
2020-05-13 2020-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 93,442 5,507 6.26 1,682 -19.37 0.0013
2020-02-10 2019-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 87,935 26,507 43.15 2,086 23.65 0.0012
2019-11-15 2019-09-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 61,428 -1,701 -2.69 1,687 -19.24 0.0011
2019-11-14 2019-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 61,428 -1,701 1,687 390.0363
2019-08-14 2019-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 63,129 -18,393 -22.56 2,089 -26.86 0.0013
2019-05-15 2019-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 81,522 12,540 18.18 2,856 24.61 0.0020
2019-02-14 2018-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 68,982 -11,961 -14.78 2,292 -43.75 0.0018
2018-11-14 2018-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 80,943 56,081 225.57 4,075 174.04 0.0028
2018-08-14 2018-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 24,862 543 2.23 1,487 33.60 0.0013
2018-05-15 2018-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 24,319 13,047 115.75 1,113 147.33 0.0009
2018-02-14 2017-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 11,272 7,964 240.75 450 238.35 0.0004
2017-11-14 2017-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 3,308 -3,547 -51.74 133 -55.07 0.0001
2017-08-14 2017-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 6,855 -1,054 -13.33 296 19.84 0.0003
2017-05-15 2017-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 7,909 5,685 255.62 247 341.07 0.0003
2017-02-14 2016-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,224 -18,063 -89.04 56 -88.82 0.0001
2016-11-14 2016-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 20,287 -96 -0.47 501 20.72 0.0006
2016-08-12 2016-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 20,383 -1,966 -8.80 415 23.88 0.0005
2016-05-16 2016-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 22,349 -10,070 -31.06 335 -20.62 0.0005
2016-02-12 2015-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 32,419 -75,905 -70.07 422 -72.20 0.0005
2015-11-13 2015-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 108,324 107,021 8,213.43 1,518 6,800.00 0.0018
2015-08-14 2015-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,303 -13,341 -91.10 22 -87.43 0.0000
2015-05-19 2015-03-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 14,644 9,676 194.77 175 337.50 0.0002
2015-05-14 2015-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 14,644 175
2015-02-13 2014-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 4,968 -11,894 -70.54 40 -70.37 0.0000
2014-11-14 2014-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 16,862 6,651 65.14 135 32.35 0.0001
2014-08-14 2014-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 10,211 -17,837 -63.59 102 -54.67 0.0001
2014-05-15 2014-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 28,048 14,013 99.84 225 129.59 0.0003
2014-02-13 2013-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 14,035 -4,381 -23.79 98 -24.03 0.0001
2013-11-14 2013-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 18,416 14,850 416.43 129 460.87 0.0002
2013-08-14 2013-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 3,566 3,566 23 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-05-13 2020-03-31 13F SUPERNUS PHARMACEUTICALS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-02-10 2019-12-31 13F SUPERNUS PHARMACEUTICALS OPT Call 160,500 69.48 3,807 46.31 n/a n/a n/a
2019-11-15 2019-09-30 13F/A SUPERNUS PHARMACEUTICALS OPT Call 94,700 2,602 n/a n/a n/a
2019-11-14 2019-09-30 13F SUPERNUS PHARMACEUTICALS OPT Call 94,700 2,602 n/a n/a n/a
2018-11-14 2018-09-30 13F SUPERNUS PHARMACEUTICALS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-08-14 2018-06-30 13F SUPERNUS PHARMACEUTICALS OPT Call 4,100 245 n/a n/a n/a
2018-02-14 2017-12-31 13F SUPERNUS PHARMACEUTICALS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-11-14 2017-09-30 13F SUPERNUS PHARMACEUTICALS OPT Call 700 250.00 28 211.11 n/a n/a n/a
2017-08-14 2017-06-30 13F SUPERNUS PHARMACEUTICALS OPT Call 200 9 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-11-15 2019-09-30 13F/A SUPERNUS PHARMACEUTICALS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-08-14 2019-06-30 13F SUPERNUS PHARMACEUTICALS OPT Put 2,700 -47.06 89 -50.28 n/a n/a n/a
2019-05-15 2019-03-31 13F SUPERNUS PHARMACEUTICALS OPT Put 5,100 112.50 179 123.75 n/a n/a n/a
2019-02-14 2018-12-31 13F SUPERNUS PHARMACEUTICALS OPT Put 2,400 80 n/a n/a n/a
2018-02-14 2017-12-31 13F SUPERNUS PHARMACEUTICALS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2017-11-14 2017-09-30 13F SUPERNUS PHARMACEUTICALS OPT Put 200 8 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.